This deodorant was just recalled — here's what you need to know
Below, find more details on what this recall means and a list of deodorants you can use instead.
Why were Power Stick deodorants recalled?
According to the FDA, 67,000 cases of Power Stick deodorant have been recalled. The recall was initiated on July 10, and it applies to the following products from the brand:
Power Stick for Her Roll-On Antiperspirant Deodorant Powder Fresh, 1.8 oz/ 53 mL UPC Code 815195019313
Power Stick Invisible Protection Roll-On Antiperspirant Deodorant Spring Fresh, 1.8 oz/53 mL UPC Code 815195018194
Power Stick Original Nourishing Invisible Protection Roll-On Antiperspirant Deodorant, 1.8 oz/53 mL UPC Code 815195018224
There was no specific reason given for the recall, only that the items were recalled for deviating from Current Good Manufacturing Practices — a set of standards established by the FDA.
Power Stick deodorant is sold at Dollar Tree, Walmart and on Amazon. No information has been given on what to do if you have already purchased one of these products, though it is usually recommended that you stop using anything that has been recalled.
Other deodorants to use instead
If the recall impacted your deodorant or you just happen to be in the market for something new, check out the recommendations below. All of them are deodorants we have either previously recommended or that have high ratings.
NBC Select associate SEO reporter Ashley Morris wasn't sure she'd like a whole body deodorant, but wound up loving this one after trying it — so much so, she wrote an entire review about it. 'I can wear this deodorant through a full day at the office, an evening workout and cooking dinner without even a hint of odor,' she says. It protects against odor for up to 72 hours and can be used all over your body, according to the brand.
For those who prefer a spray, Dove makes a great option. It dries clear and offers 48-hours of protection, according to the brand. It also comes in several scents, so you can choose one that best suits your preferences. Hold it six inches away from your underarm and apply it in two to three short bursts.
The stick version of this deodorant was recommended in our guide to the best deodorants. This one has a roll-on top, similar to the recalled products. It contains 15% aluminum chloride (the highest strength available over-the-counter) to help stop sweating, according to the brand. It is fragrance-free and offers 72-hour protection. It has a 4.2-star average from 39,658 reviews on Amazon.
Why trust NBC Select?
Bethany Heitman is a contributor at NBC Select and a journalist who regularly covers topics like beauty, home and lifestyle.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Daily Mail
17 hours ago
- Daily Mail
Scientists discover two drugs already approved by the FDA can reverse Alzheimer's
Two drugs already approved by the FDA for cancer treatment may hold the key to reversing Alzheimer's disease in patients, experts say. Researchers from the University of California, San Francisco (UCSF) believe that letrozole, a hormone-based breast cancer drug, and irinotecan, a lung and colon cancer chemotherapy medication, can help reverse brain damage caused by the incurable neurodegenerative disease. In an animal study, the UCSF experts found that both cancer drugs were seen to reduce brain degeneration in mice and even improve their memory and learning capacity. Alzheimer's disease is one of the most common forms of dementia and mostly affects adults over the age of 65. About 7million Americans live with the condition and over 100,00 die from it annually. The disease is believed to be caused by the development of toxic amyloid proteins and/or tau proteins in the brain, which can accumulate and damage cells responsible for memory and learning. Amyloid protein molecules stick together in brain cells, forming clumps called plaques. While tau proteins twist together in fiber-like strands called tangles. As of now, there is no cure for AD and only two FDA-approved therapies, Lecanemab (Leqembi) and Donanemab (Kisunla), are available for early-stage Alzheimer's treatment. However, because letrozole and irinotecan are already approved for other treatments, this could fast-track clinical trials and the potential approval for use in Alzheimer's patients. Co-senior author Dr Marina Sirota, a professor at UCSF, said: 'Alzheimer's disease comes with complex changes to the brain, which has made it tough to study and treat, but our computational tools opened up the possibility of tackling the complexity directly. 'We're excited that our computational approach led us to a potential combination therapy for Alzheimer's based on existing FDA-approved medications.' In Alzheimer's patients, the plaques and tangles block the ability of the brain's neurons to send electrical and chemical signals back and forth. Over time, this disruption causes permanent damage in the brain that leads to Alzheimer's and dementia, causing patients to lose their ability to speak, care for themselves and interact with the world around them. While the exact mechanisms of how the Alzheimer's-related brain damage begins are still under investigation, age and genetics are known risk factors. Experts also believe that lifestyle factors such as physical inactivity and high blood pressure can also contribute to the development of Alzheimer's. Despite rigorous preclinical and clinical research efforts, drug development for dementia faces significant challenges, with a 98 percent failure rate in recent decades. Neuroscientist Dr Yadong Huang, co-author of the study and professor of neurology at UCSF, explained: 'Alzheimer's is likely the result of numerous alterations in many genes and proteins that, together, disrupt brain health. 'This makes it very challenging for drug development – which traditionally produces one drug for a single gene or protein that drives disease.' However, researchers at USCF believe their discovery can help reduce or reverse the cognitive decline caused by the disease. First, the team looked at how dementia changes gene expression in the brain. Then, they scoured a database of over 1,300 drugs, including antipsychotics, antibiotics, antifungals and chemotherapy drugs, to determine which, if any, reversed any of these gene expressions. If any existing drugs were found to be effective, they could be repurposed to treat the condition in a reduced the time in which the drugs could be made available to patients. During their search, the team specifically looked for drugs that would target the harmful Alzheimer's-related changes in neurons and in brain cells called glia that are responsible for supporting the nervous system. Then, the researchers analyzed millions of digital medical records to find patients who took some of these drugs as part of cancer treatments and their likelihood of developing Alzheimer's. Ultimately, they identified letrozole and irinotecan as the best candidates to lower Alzheimer's risk in patients. By combining the two drugs together, the researchers were able to target different types of brain cells affected by the disease. They noted that letorozole could counter the effect of Alzheimer's on neurons and irinotecan helped reverse damage on the glia cells. When the combination was tested on mice, the scientists saw that the harmful clumps of tau protein were reduced significantly and the mice showed improvements in learning and memory tasks. The study authors noted that it remains unclear how the cancer drugs are able to reverse the damage. However, they theorized that it was possible that letrozole blocks the production of estrogen, a hormone that controls the working of a large number of genes, which therefore reduces the genetic risk factor of developing Alzheimer's. Additionally, they believe that irinotecan may also block inflammation in the brain by preventing the rapid reproduction and DNA damage of glial cells. As this was an animal study, the researchers hope to test the drugs in a clinical trial with human Alzheimer's patients. Dr Huang said of the results: 'Developing a new drug can take hundreds of millions, or even billions, of dollars, on average take more than 10 years. For this repurposed drug, usually it just takes two or three years, and then you can go to the clinical trial and the cost is much, much lower. 'We still haven't generated or produced any very effective drugs that can really slow dramatically the cognitive decline.' However, despite their groundbreaking discovery, risks continue as letrozole is known to cause hot flashes in patients while irinotecan can cause severe diarrhea. Both drugs can also lead to nausea and vomiting. Dr Sirota said: 'These drugs have huge side effects, so you need to always balance and figure out whether those types of side effects would be amenable to somebody with Alzheimer's. It's not that it's a slam dunk.'
Daily Mail
17 hours ago
- Daily Mail
Everything you need to know about the risks of antidepressants in pregnancy – and why some top doctors say mums-to-be should stop taking them
Leading medical experts have called for women to stop taking antidepressants during pregnancy over fears that they could cause harm to unborn children. Doctors speaking at a prestigious panel of the US drugs safety watchdog, the Food and Drugs Administration (FDA), on Monday warned that there was 'accumulating evidence' that antidepressants known as selective serotonin reuptake inhibitors, or SSRIs, were linked to birth defects and may harm the developing infant brain.
Reuters
2 days ago
- Reuters
FDA probes death of patient on Sarepta's Elevidys, partner Roche says death unrelated to therapy
July 25 (Reuters) - The U.S. Food and Drug Administration said on Friday it was investigating the death of an eight-year-old boy who received Sarepta Therapeutics' (SRPT.O), opens new tab muscular disorder gene therapy Elevidys. The death occurred on June 7, the agency said, sending shares of the company down more than 3% in extended trading. The patient with Duchenne muscular dystrophy, who died in Brazil, was treated with Elevidys but was not a participant in a clinical trial, Roche, which partners with Sarepta outside the U.S., told Reuters in an email. The reporting physician has assessed the death as unrelated to treatment with the gene therapy, Roche said, adding that the death was reported to the health authorities as required per local regulations, and that it was continuing to gather and analyze the information from this event. Sarepta has come under intense regulatory scrutiny after two non-ambulatory teenage boys died due to acute liver failure associated with Elevidys, and a 51-year-old man who had received its experimental gene therapy SRP-9004 died from the same condition. Late on Monday, the company said it would comply with a request from the FDA to pause all shipments of Elevidys in the United States. Its partner Roche also paused Elevidys shipments in some countries outside the U.S. later. The FDA's request had come after the company disclosed the death of the patient on SRP-9004.
